Skip to main content

HARVARD BIOSCIENCE INC

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

HBIO$9.26+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except per share data)
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenues$22,196$20,591$65,678$62,815
Cost of revenues9,8898,57028,49727,077
Gross profit12,30712,02137,18135,738
Sales and marketing expenses5,4204,61316,15514,123
General and administrative expenses4,7564,17614,07513,623
Research and development expenses2,2582,1327,0376,642
Amortization of acquired intangible assets3658552,0053,177
Goodwill impairment - Note 4---47,951
Other operating expenses - Note 12658481,211512
Total operating expenses13,45711,82440,48386,028
Operating (loss) income(1,150)197(3,302)(50,290)
Other income (expense):
Interest expense(1,783)(1,323)(5,304)(3,257)
Other income (expense), net238(8)(292)(635)
Total other expense(1,545)(1,331)(5,596)(3,892)
Loss before income taxes(2,695)(1,134)(8,898)(54,182)
Income tax (benefit) expense(72)9759(329)
Net loss$(2,623)$(1,231)$(8,957)$(53,853)
Loss per share:
Basic and diluted loss per share *$(0.58)$(0.28)$(1.99)$(12.15)
Weighted-average common shares:
Basic and diluted *4,5614,4564,5004,432
*Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.